Celularity Inc current report, 17 March 2023

Vollständiges Dokument

Celularity Inc. Form 8-K Summary

Business Context and Reporting Period

Celularity Inc. filed a Current Report on Form 8-K dated March 23, 2023, reporting events occurring on March 17 and March 20, 2023. The filing concerns new financing arrangements, an unregistered equity issuance, and a binding term sheet for a sublicense. It does not provide quarterly or annual operating results.

Key Financial and Capitalization Matters

  • Private placement: Celularity agreed to sell 9,381,841 shares of Class A common stock and accompanying warrants for aggregate proceeds of approximately $9.0 million. The stock purchase price was $0.8343 per share, and each accompanying warrant was priced at $0.125.
  • PIPE warrants: The warrants cover up to 9,381,841 shares, are immediately exercisable at $3.00 per share, and expire March 24, 2028. They contain customary anti-dilution adjustments and beneficial ownership exercise limitations.
  • Senior secured bridge loan: On March 17, 2023, Celularity closed a $5.0 million principal loan, net of a $100,000 original issue discount, from C.V. Starr & Co. Inc. The loan bears 12.0% annual interest, with interest for the first year paid in kind monthly, and matures March 17, 2025.
  • Starr warrant: In connection with the loan, Celularity issued a warrant to purchase up to 750,000 shares. The warrant has a five-year term and an exercise price of $0.71 per share; the purchase price for the warrant was $93,750.
  • Use of proceeds: Financing proceeds are intended for working capital and general corporate purposes, including the sublicense payment.
  • Sublicense consideration: Celularity paid $3.0 million in cash and issued $1.0 million of Class A common stock, or 1,694,915 shares based on the March 17 closing price, under a binding term sheet for a sublicense of certain assets.
  • Liquidity restriction: The bridge loan agreement restricts Celularity from allowing cash and cash equivalents to remain below $3.0 million for more than five consecutive business days.

Material Changes Versus the Prior Comparable Period

The filing does not provide prior-period financial statements or operating metrics for comparison. Relative to the previously reported capital structure, the transactions increase cash resources but also add senior secured debt, warrant obligations, interest expense, and potential common-stock dilution.

Guidance, Outlook, Risks, and Unusual Items

  • The private placement closing was expected on or around March 24, 2023 and remained subject to customary closing conditions.
  • Celularity granted Starr a senior security interest in all of its assets.
  • The loan includes customary negative covenants limiting additional indebtedness, debt repayment, dividends, and liens, subject to permitted exceptions, as well as customary events of default.
  • The private placement securities were issued under the Section 4(a)(2) and Regulation D exemptions and were not registered under the Securities Act or applicable state securities laws.
  • Celularity agreed to register the resale of the private placement shares, warrant shares, and shares issued as sublicense consideration. The registration statement was required to be filed within 30 days after filing the 2022 Form 10-K and, subject to SEC review timing, declared effective no later than June 30, 2023.
  • The sublicense was described only through a binding term sheet; the filing does not provide a complete valuation, detailed commercial terms, or the expected financial contribution of the sublicensed assets.
  • Dr. Robert Hariri, Celularity’s Chairman and Chief Executive Officer, subscribed for $2.0 million of the private placement, creating a related-party participation in the financing.

Important Facts for Investors to Verify

  1. Whether the approximately $9.0 million private placement closed as expected and the final number of shares and warrants issued.
  2. The closing status and terms of the sublicense agreement, including the assets obtained and any additional payments or obligations.
  3. Celularity’s post-transaction cash balance and compliance with the $3.0 million minimum liquidity covenant.
  4. The senior secured loan balance, accrued paid-in-kind interest, collateral coverage, and compliance with all covenants.
  5. The dilution impact from the 9,381,841 PIPE warrants, the 750,000 Starr warrants, and the 1,694,915 shares issued for sublicense consideration.
  6. Whether the required resale registration statement was filed and became effective within the stated deadlines.